Related Experiment Videos
Myocardial ischemia associated with high-dose carmustine infusion
S S Kanj1, A I Sharara, E J Shpall
1Department of Internal Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Cancer
|November 1, 1991
Summary
High-dose Carmustine (BCNU) infusions may cause myocardial ischemia in patients without prior heart conditions. This cardiac toxicity needs consideration during treatment.
Area of Science:
- Oncology
- Cardiology
- Pharmacology
Background:
- Carmustine (BCNU), a nitrosourea derivative, is an antineoplastic agent.
- BCNU is utilized in high doses for treating solid tumors and lymphomas, often with autologous bone marrow transplantation.
- Cardiac toxicity associated with BCNU is not well-documented.
Observation:
- Three patients without a history of angina pectoris were studied.
- These patients exhibited clinical and electrocardiographic evidence of myocardial ischemia.
- The ischemic events occurred during and immediately following BCNU infusion.
Findings:
- Carmustine (BCNU) administration was linked to acute myocardial ischemia in the observed patients.
- The incidence, etiology, and precise mechanism of this BCNU-induced cardiac side effect remain undetermined.
- This suggests a potential cardiotoxic effect of high-dose BCNU.
Implications:
- Healthcare providers should be aware of the potential for BCNU-induced myocardial ischemia.
- Cardiac monitoring may be warranted for patients undergoing high-dose Carmustine therapy.
- Further research is needed to elucidate the mechanism and incidence of this adverse event.